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Abstract
Background: Symptom prevalence is generally believed to increase with age. The aim of this study
was to evaluate the age specific prevalence of 30 general symptoms among Swedish middle-aged
women.
Methods: A cross-sectional postal questionnaire study in seven Swedish counties in a random
sample of 4,200 women 35–64 years old, with 2,991 responders. Thirty general symptoms included
in the Complaint Score subscale of the Gothenburg Quality of Life Instrument were used.
Results: Four groups of age specific prevalence patterns were identified after adjustment for the
influence of educational level, perceived health and mood, body mass index, smoking habits, use of
hormone replacement therapy, and use of other symptom relieving therapy. Only five symptoms
(insomnia, leg pain, joint pain, eye problems and impaired hearing) increased significantly with age.
Eleven symptoms (general fatigue, headache, irritability, melancholy, backache, exhaustion, feels
cold, cries easily, abdominal pain, dizziness, and nausea) decreased significantly with age. Two
symptoms (sweating and impaired concentration) had a biphasic course with a significant increase
followed by a significant decrease. The remaining twelve symptoms (difficulty in relaxing,
restlessness, overweight, coughing, breathlessness, diarrhoea, chest pain, constipation,
nervousness, poor appetite, weight loss, and difficulty in urinating) had stable prevalence with age.
Conclusion: Symptoms did not necessarily increase with age instead symptoms related to stress-
tension-depression decreased.
Background
The burden of morbidity increases with increasing age,
while the prevalence of symptoms seems to be less age
dependent. If symptom prevalence mirrors disease preva-
lence then symptom prevalence should also increase with
age. However, although symptoms may indicate disease
they may also be attributable to the physiological effects
of anxiety or other emotions arising from a personal prob-
lem [1]. Moreover, in addition to age, symptom reporting
may be influenced by socioeconomic and lifestyle factors,
such as educational level, physical activity, profession,
income level, and social interaction [2-5].
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Several studies have shown that women of all ages report
more symptoms, take more of both prescription and non-
prescription medication and consult physicians more
often than men [6-8]. One possible explanation may be
that women are more attentive to their wellbeing (physi-
cal and psychological), and therefore seek medical atten-
tion based on perception of their symptoms. Middle-aged
women often present a variety of complaints at the onset
of the menopause. It has been claimed that the menopau-
sal syndrome is related more to personal characteristics
than to the menopause per se, and that women in meno-
pausal transition with several complaints of other origin
than vasomotor may be suffering from underlying depres-
sion [9].
Complaint Score is a subscale of the Gothenburg Quality
of Life instrument and contains a list of 30 symptoms. The
subscale is intended to measure the tendency to report
symptoms based on the assumption that symptom report-
ing reflects wellbeing. The instrument has been widely
used during the last 30 years among men and women. It
has been shown that symptom prevalence does not neces-
sarily increase with age [1]. We decided to test the hypoth-
esis that some symptoms increase with age whereas other
have a decreasing or stable tendency in young to middle-
aged women sampled from the general population.
Methods
A random sample of 4200 women aged 35–64 years was
drawn from the population register of the seven counties
comprising the Uppsala-Örebro Health Care Region in
central Sweden, a region large enough to be representative
of Sweden. A postal questionnaire was sent to these
women and 2991 (71.2%) responded. The age distribu-
tion of responders (49.6 ± 8.5 years) and non-responders
(49.8 ± 8.7 years) was similar.
The questionnaire consisted of two parts. The first part
contained information on height and weight, social back-
ground, lifestyle, medical history, gynaecological and
obstetric history, and quality of life. Educational level was
classified as compulsory education only, vocational train-
ing, high school, or college/university education. The
women were classified according to their smoking habits
as never-smokers, ex-smokers and current smokers. Body
mass index was calculated as weight (kg)/height (m)2.
The gynaecologic/obstetric data include number of preg-
nancies, ever use of contraceptives, menstrual status and
ever undergone a hysterectomy or ooforectomy.
The Gothenburg Quality of Life Instrument was used to
measure quality of life aspects [10]. For this report the
Complaint Score and Well-being sub-scales were used.
The Complaint Score is a list of 30 general symptoms. The
women were asked to indicate which of the symptoms
they had experienced during the past three months. Possi-
ble responses were "yes" or "no". At test-retest of the
instrument a Spearman correlation coefficient of 0.54 was
found even with seven years between test and retest and
probably much higher with shorter interval. Of the well-
being subscale questions, those on work situation, per-
ceived health, physical fitness, mood, energy, patience,
self-esteem, and being appreciated at home or outside the
home were used in this study. The responses were given
on seven-point interval scales ranging from "poor" (= 1)
to "excellent, could not be better" (= 7). The correspond-
ing test-retest correlation coefficient as above was 0.49 for
mood and 0.46 for health.
The second part of the questionnaire focused on drugs
prescribed during the past 12 months. For each prescrip-
tion, information was collected on drug trade name, indi-
cation, dosage, duration of medication, and whether or
not the woman was taking the drug currently. All pre-
scribed drugs reported were coded according to the Ana-
tomical Therapeutic Chemical Classification System
(ATC) [11]. For this report, information on hormone
replacement therapy (ATC codes G03C and G03F) and
symptom relieving therapy (tranquilizers, hypnotics, anti-
depressants and painkillers with ATC codes N02A, N02B,
N05B, N05C, N06A, M01A and M03B) was used. The
study was approved by the Research Ethics Committee at
Uppsala University.
Statistical analysis
Statistical analyses were conducted using the SAS [12] pro-
gramme package. First, preliminary analyses of symptom
prevalence in relation to age were performed with univar-
iate and multivariate logistic regression analyses, with
symptom reporting (yes/no) as the dependent variable,
and age and 18 other potential outcome affecting varia-
bles (education, physical fitness, smoking habits, body
mass index, perceived work situation, health, mood,
energy, self-esteem, patience, appreciated at home or out-
side the home, number of pregnancies, ever use of contra-
ceptives, hormone replacement therapy, other symptom
relieving medication, menstrual status, and hysterectomy
or ooforectomy ever performed), as independent varia-
bles with backward elimination of non-significant varia-
bles. In addition, a square term for age and a number of
potential interaction terms were tested.
A final set of independent variables (covariates) common
for all symptoms and significantly related to most of them
was then defined. In addition to age it included perceived
health, perceived mood, educational level, body mass
index, smoking habits, use of hormone replacement ther-
apy, and use of other symptom relieving medication, and
age squared for curvilinear functions. No interaction
terms survived the preliminary analyses.BMC Public Health 2009, 9:37 http://www.biomedcentral.com/1471-2458/9/37
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Based on the final logistic regression analyses, age specific
symptom prevalence estimates, adjusted for the influence
of the final set of covariates listed above, were computed.
The fit of adjusted functions to crude data regarding func-
tional form was excellent for all 30 symptoms. The adjust-
ments only affected the prevalence levels and only
moderately.
A power analysis was performed regarding the age effect
on one symptom each in the prevalence increase, decrease
and no change group. The power, given a study popula-
tion of 2900, an alpha level of 0.01, and the slopes found
in the study, was 99.9% for general fatigue and 90% for
insomnia. For nervousness, where there was no significant
change with age, more than 30,000 subjects would have
been needed to reach 80% statistical power to detect an
age related prevalence change.
All tests were two-tailed. In the preliminary analyses p <
0.05 was used. In the final analyses p < 0.01 for symptom
trend across age was used to account for multiple testing.
Results
Characteristics of the study population are given in Table
1. The mean age was 49.6 years, inter-quartile range 42–
56. More than one fourth of the women had a university
education and one fourth were smokers. Mean body mass
index was 24.8, inter quartile ranged 22.2–26.8. The
majority reported their mood and perceived health as
moderately good or good. Hormone replacement therapy
was currently used by 15%, and other symptomatic reliev-
ing medication by 13%.
The prevalence of the 30 symptoms among all women in
the study are shown in Figure 1. The most prevalent symp-
toms were general fatigue (64.2%), headache (54.9%),
melancholy (53.7%), irritability (48.1%), and backache
(47.1%). The least prevalent were difficulty urinating
(3.1%), weight loss (3.1%), poor appetite (5.7%), consti-
pation (13.0%), and diarrhoea (14.0%). The prevalence
of the 30 symptoms by 5-year age groups, after adjust-
ments for the influence of educational level, perceived
health and mood, body mass index, smoking habits, use
of hormone replacement therapy, and use of other symp-
tom relieving therapy, is presented in Table 2. Four symp-
toms: insomnia, leg pain, eye problems and impaired
hearing, all increased significantly by age with 8–10 per-
cent from the youngest age group to the oldest age group.
Joint pain has showed a similar but inconclusive increase.
An example from this group, impaired hearing, is pre-
sented as a graph in Figure 2.
Twelve symptoms, difficulty relaxing, restlessness, over-
weight, coughing, breathlessness, diarrhoea, chest pain,
constipation, nervousness, poor appetite, weight loss, and
difficulty urinating, had a stable prevalence with age,
ranging from 41.3% to 1.9%. An example from this
group, coughing, is also shown on the graph in Figure 2.
Two symptoms, impaired concentration and sweating,
had biphasic prevalence. Impaired concentration
increased from 28% among the youngest women, to a
peak value of 32% at ages 45–49 and then decreased to
22% at age 60–64. Sweating had an even more pro-
nounced biphasic course starting at 14% among the
youngest, reaching a maximum level of 38% at ages 50–
54 years and then decreasing to 28% among the oldest
subjects. The prevalence course for sweating is shown in
Figure 2.
The remaining eleven symptoms, general fatigue, head-
ache, irritability, melancholy, backache, exhaustion, feel-
ing cold, crying easily, abdominal pain, dizziness, and
nausea, all showed a significantly decreasing prevalence
with age. For many of the symptoms the prevalence at age
60–64 was half or less of what it was among the youngest
women. General fatigue, shown in Figure 2, ranged from
83.4% among the youngest to 47.8% among the oldest
women. Corresponding levels for headache were 74.2%
Table 1: Characteristics. 
n mean or %
Age (years) 2991 49.6 ± 8.5
Educational level
Compulsory school only 831 28.5
Vocational school/high school 1299 44.5
College or university 787 27.0
Smoking habits
Never smoked 1315 45.1
Ex-smoker 838 28.7
Current smoker 763 26.2
Body mass index (kg/(m2))
15–24 1704 59.3
25–30 888 30.9
>30 201 9.8
Mood
Poor (1–3) 207 7.1
Moderately good or good (4–6) 2182 74.6
Excellent (7) 534 18.3
Self-rated health
Poor (1–3) 338 11.6
Moderately good or good (4–6) 2020 69.1
Excellent (7) 564 19.3
Hormone replacement therapy
no use 2428 82.7
current use 441 15.0
past use 67 2.3
Symptom relieving therapy
no use 2450 83.4
current use 375 12.8
past use 111 3.8
Psycho-socio-economic characteristics of the study population.BMC Public Health 2009, 9:37 http://www.biomedcentral.com/1471-2458/9/37
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and 35.5%, respectively, Table 2. Irritability ranged from
66.1% to 30.5% and backache from 55.2% to 39.6%.
Discussion
The study revealed that the symptoms examined could be
grouped into four prevalence patterns. Only five symp-
toms increased with age, twelve symptoms had stable
prevalence, two had a biphasic course (first increasing and
then decreasing) and eleven symptoms had decreasing
prevalence with age after adjustment for the influence of
the final set of covariates on symptom prevalence, thereby
making prevalence estimates in various age groups more
accurate and comparable.
This study was performed in a random population sample
of women aged 35–64 years. The response rate was satis-
factory (71%). However, the 29% non-responders may
imply a potential selection bias in the estimation of the
proportion of women reporting symptom, if responders
and non-responder had different characteristics. The dis-
tribution of socioeconomic variables and drug use among
the responders was similar to that of national samples in
Sweden [13,14]. The size of the potential bias caused by
non-response was estimated in a previous publication
[15] and found to be of relatively little importance. Symp-
tom reporting may have been affected by recall bias. How-
ever, the recall period of the last 3 months was short and
Table 2: Symptom prevalence data. 
Age groups p across age *)
35–39 40–44 45–49 50–54 55–59 60–64
n 426 514 602 541 418 490
Increasing prevalence
Insomnia 28.1 30.0 32.0 34.1 36.2 38.4 <0.005
Leg pain 27.0 28.8 30.7 32.7 34.7 36.7 <0.005
Joint pain 27.0 28.5 30.1 31.7 33.3 35.0
Eye problems 16.2 20.7 24.3 26.2 26.3 24.6 <0.005
Impaired hearing 9.4 10.9 12.6 14.6 16.8 19.3 <0.0001
Stable prevalence
Difficulty relaxing 37.1 40.0 41.3 41.0 39.1 35.8
Restlessness 35.3 34.4 33.5 32.5 31.6 30.7
Overweight 32.5 32.8 33.2 33.5 33.8 34.1
Coughing 23.7 23.7 23.8 23.9 24.0 24.0
Breathlessness 16.6 17.1 17.5 18.0 18.5 18.9
Diarrhoea 16.1 13.3 11.7 11.2 11.5 12.7
Chest pain 12.2 12.3 12.5 12.6 12.8 13.0
Constipation 12.2 12.1 11.9 11.8 11.6 11.5
Nervousness 10.7 11.0 11.3 11.7 12.0 12.4
Poor appetite 5.4 3.7 2.9 2.7 2.8 3.4
Weight loss 2.6 2.5 2.3 2.2 2.0 1.9
Difficulty urinating 2.2 2.2 2.2 2.2 2.2 2.2
Biphasic prevalence
Impaired concentration 28.1 31.3 32.2 30.7 27.0 21.6 <0.001
Sweating 14.1 25.0 34.1 38.1 35.9 28.2 <0.0001
Decreasing prevalence
General fatigue 83.4 78.2 71.8 64.4 56.3 47.8 <0.0001
Headache 74.2 67.3 59.7 51.5 43.3 35.4 <0.0001
Irritability 66.1 59.1 51.8 44.4 37.2 30.5 <0.0001
Melancholy 60.1 58.3 56.4 54.6 52.7 50.8 <0.01
Backache 55.2 52.1 48.9 45.8 42.7 39.6 <0.0001
Exhaustion 45.4 45.6 43.2 38.1 30.9 22.5 <0.001
Feeling cold 40.7 36.0 31.6 27.5 23.7 20.3 <0.0001
Crying easily 38.6 35.5 32.4 29.5 26.8 24.3 <0.0001
Abdominal pain 32.2 28.7 25.4 22.3 19.6 17.1 <0.0001
Dizziness 27.3 24.9 22.6 20.6 18.6 16.8 <0.0005
Nausea 17.9 15.7 13.6 11.8 10.2 8.8 <0.0001
Symptom prevalence by age after adjustment for the influence of educational level, self-rated health and mood, body mass index, smoking habits, use 
of hormone replacement therapy, and use of other symptom relieving therapy.
*)p-values refer to prevalence trends across age.BMC Public Health 2009, 9:37 http://www.biomedcentral.com/1471-2458/9/37
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the age range was such that younger and older women
may be expected to have similar recall capacity.
The most commonly reported symptoms by the women
in this study irrespective of age were general fatigue, head-
ache, irritability, melancholy and backache, occurring in
over or around 50% of the subjects. Furthermore, one
third or more of the women had symptoms such as
insomnia, restlessness, exhaustion and crying easily. Gor-
man has reviewed gender differences in the epidemiology
and clinical presentations of depression [16]. In the
United States, 1 out of 5 women suffered from an episode
of major depression at some time in her life. Depression
was about twice as common among women as among
men. Women were more likely to have atypical symptoms
of depression such as hypersomnia and hyperphagia, or to
have co-morbid anxiety disorders or to attempt suicide
than men.
It has previously been shown by Tibblin et al., that there
are different symptom prevalence patterns with age [1].
They studied 30 general symptoms in women and men
and found generally higher symptom prevalence in
women, using the same symptom questionnaire as used
in this study. Three symptom patterns were found:
increasing, decreasing, and biphasic prevalence, whereas
four patterns, increasing, decreasing, biphasic, and stable
were seen in the present study. The study by Tibblin et al.
was performed some twenty years ago and no adjustments
were made to make the age groups more comparable,
which might explain the differences found in the two
studies [1].
Five symptoms increased with age. It is a well-established
fact [1] and is part of the normal ageing process, that hear-
ing and vision deteriorate with age. Sleep disturbance has
also been found by others to increase with age. It has been
Symptom prevalence Figure 1
Symptom prevalence. Three months prevalence (%) of 30 symptoms among women 35–64 years of age.BMC Public Health 2009, 9:37 http://www.biomedcentral.com/1471-2458/9/37
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shown in a longitudinal study, that sleep duration
decreased by 0.4 hours per night for women aged 38–66
years and that sleep problems increased by 30% for
women aged 38–84 years [17,18].
In this study it was seen that leg pain as well as joint pain
increased with age. This might partly be explained by
increasing weight in those age groups. However, differ-
ences in body mass index between the groups were
adjusted for, making overweight a less likely cause of these
symptoms. Alternately, leg pain and joint pain could be
signs of other musculoskeletal disorders, like osteoarthri-
tis or rheumatoid arthritis, both of which have increasing
prevalence with age [19,20].
One third of the symptoms studied had stable prevalence
patterns. This is in contrast to prior findings where
increasing, decreasing and biphasic courses have been
reported [1]. We found stable prevalence patterns for dif-
ficulty in relaxing and nervousness, in contrast to the sim-
ilar symptoms in the decreasing group. However,
difficulty in relaxing and nervousness may indicate a per-
sonality trait rather than an age-related development.
Also, symptoms like coughing, breathlessness and chest
pain showed a similar unchanged pattern of relatively low
prevalence, ranging from 12.2% to 23.7% among women
ages 35 to 39 years indicating a more innocent nature of
the symptoms than what it might have been in older age
groups.
The prevalence of overweight, constipation, weight loss,
and difficulty in urinating were also stable with age. Some
of these symptoms, such as poor appetite, weight loss and
difficulty in urinating, are commonly associated with seri-
ous diseases including diabetes and cancer, while consti-
pation is common among the elderly. In this study
overweigh ranged with age from 32.5% to 34.1%. This is
broadly in line with what others found [21].
Two commonly considered groups of symptoms in
women during the menopausal transition are psychologi-
cal and vasomotor symptoms [22-27]. However, many
symptoms believed to be related to the menopause also
occur before and after this phase [15]. Only two symp-
toms in our study showed a biphasic pattern, possibly
suggesting their association with the menopausal transi-
tion. Impaired concentration had a peak, with a maxi-
mum prevalence of 32.2% at the ages of 45–49 years,
Examples of prevalence course across age Figure 2
Examples of prevalence course across age. The four groups of symptom prevalence represented by four typical symp-
toms.BMC Public Health 2009, 9:37 http://www.biomedcentral.com/1471-2458/9/37
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which is in agreement with findings reported by Tibblin et
al. [1]. Increased prevalence of sweating was seen between
the ages of 40 and 59, which is in line with what others
have found [26,28].
Eleven symptoms had decreasing prevalence patterns with
age: general fatigue, headache, irritability, melancholy,
backache, exhaustion, feeling cold, crying easily, abdomi-
nal pain, dizziness and nausea. The prevalence for head-
ache ranged from 74.2% among the youngest women to
35.4% among the oldest women in our study. It is known
that headache prevalence decreases after 50 years of age
[1], both for migraine and other types of headache [29].
A decrease in the prevalence of backache from 55.2% to
39.6% with age was seen in this study. Low back pain
mostly occurs in an individual's most productive years,
with a peak in the age interval 35–59 years [30-32], which
is in line with the results presented. Abdominal pain and
nausea decreased with age as well. These two symptoms
were less common at the older end of the age range than
at the younger end. In a recent UK primary care study the
incidence of abdominal pain in women was seen to
decrease between the ages of 35 and 60, where after which
a slight increase could be seen [33].
The findings from the present study may be useful for
public health administrators in forming health policies.
They may also be used in a clinical setting where doctors
are giving advice to their patients. Since the major part of
the symptoms become less prevalent with age, other strat-
egies than pharmacological treatment may come into per-
spective.
Conclusion
Four prevalence courses across age were found. Few symp-
toms increased by age. The majority were either stable or
decreased. Of those that decreased, the majority are gener-
ally associated with stress, strain or depression. The rea-
sons why these symptoms generally decrease with age
may be that women at the lower end of the age range have
a larger burden with family, children and career than
older women have, when the children may be grown up
and their careers may be more stable. Symptoms do not
necessarily increase with age, indicating that they may
have other causes than ageing or disease.
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